I. Overview: Hepatic hemangioma is a benign tumor of the liver. Hepatic cavernous hemangioma is the most common. Cavernous hemangioma is usually solitary and occurs mostly in the right lobe of the liver, about 10% are multiple, and is more common in middle-aged women, with the incidence rate of women being six times higher than that of men. This disease has no obvious symptoms and only shows occupying lesions in the liver, so clinical attention should be paid to differentiate it from liver cancer. Clinical manifestations: Early stage may be asymptomatic, but when the tumor is large, there may be swelling and pain in liver area, large liver or palpable mass. Diagnostic basis: 1.Abdominal ultrasound is the preferred method for early diagnosis. 2.CT examination: There is a low-density area with uniform density in the liver, and a “C”-shaped enhancement zone may appear in the edge of the tumor after enhancement. 3.Hepatic arteriogram: “vascular lake and vascular pool” images appear around the lesion site, and the retention time of contrast agent is longer. Treatment: At present, there is no effective drug for hepatic hemangioma, so if the hemangioma is <5cm, it is not necessary to seek medical help everywhere, and regular follow-up can be done. If the tumor is >5cm and there are self-conscious symptoms, further treatment is needed. The traditional method is surgical resection, which is very traumatic, painful, expensive and risky for patients. With the development of interventional radiology, the minimally invasive treatment (hepatic artery DSA + embolization) has been developed to the point of perfection, and it is possible to cure hepatic hemangioma by using interventional technology, without the need to “open up the abdomen”, only a small 2mm incision in the groin area can achieve the purpose of cure, and has the advantages of high safety, low pain and low cost. It has the advantages of high safety, low pain and low cost.